ResMed stock holds its US listing focus. Business context stays central.

ResMed stock centers on its sleep and respiratory care franchise, with Nasdaq-listed exposure and a global device and digital health footprint.

ResMed (AU000000RMD6) is a global medical technology company focused on sleep apnea treatment, respiratory care, and connected health software. The company trades on Nasdaq through its US listing, giving US investors a direct market reference for the stock.

Business model

ResMed sells masks, devices, and cloud-connected software that support therapy adherence and home-based care. Its model blends recurring revenue from consumables and digital services with a larger installed base of therapy devices.

US market reference

For US investors, the Nasdaq listing is the key trading venue and the stock sits inside the broader US healthcare technology complex. That keeps the company tied to reimbursement trends, sleep-disorder diagnosis rates, and demand for remote patient monitoring.

Representative product

A core product family is the company's sleep apnea therapy platform, which combines devices, masks, and connected monitoring tools. The product line is central to ResMed's identity because it links hardware sales with ongoing patient use and software-enabled follow-up.

Stock context

ResMed shares trade on Nasdaq in US dollars. The company is widely followed by healthcare and medical-device investors because its revenue mix combines consumer-facing therapy equipment with digital care software.

ResMed at a glance

• Company: ResMed Inc.
• ISIN: AU000000RMD6
• Ticker: RMD
• Exchange: Nasdaq
• Sector / Industry: Healthcare / Medical Devices
• Index membership: not stated
• Next earnings date: not yet officially scheduled